Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Mesoblast in the transaction. Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented BridgeBio in the transaction. BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a...
You must be a Standard 1 Year member to access this content.
Khaitan & Co. advised global co-ordinators and the book running lead managers on the deal, while IndusLaw and Trilegal advised the selling shareholders on the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Stonepeak Partners in the transaction. Simpson Thacher advised Blackstone Real Estate Partners VII on the transaction. Blackstone (NYSE: BX) has announced that...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Maples and Calder represented Connect Biopharma in the transaction. Global Law Office and Davis Polk advised joint book-running managers. Connect Biopharma...
You must be a Standard 1 Year member to access this content.
